跳至主導覽 跳至搜尋 跳過主要內容

Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma

  • Wei Chen Lee*
  • , Hao-Chien Hung
  • , Jin-Chiao Lee
  • , Yu Chao Wang
  • , Chih Hsien Cheng
  • , Tsung Han Wu
  • , Chen Fang Lee
  • , Ting Jung Wu
  • , Hong Shiue Chou
  • , Kun Ming Chan
  • *此作品的通信作者
  • Chang Gung Memorial Hospital
  • Chang Gung University

研究成果: 期刊稿件 › 文章 › 同儕審查

4 引文 斯高帕斯(Scopus)

摘要

Background: Therapeutic effect and immunosuppressor cell alteration in adding transcatheter arterial chemoembolization (TACE) to sorafenib for advanced stage hepatocellular carcinoma (HCC) remain unclear. Aims: To examine the therapeutic effect and immunosuppressor cell alteration in adding TACE to sorafenib. Methods: Forty-four advanced stage HCC patients were divided into group A (n = 17) treated by sorafenib (400-600 mg/day) alone and group B patients (n = 27) treated by sorafenib and TACE. The frequency of regulatory T-cells and myeloid-derived suppressor cells (MDSC), and patients' outcomes were examined. Advanced HCC patients' survival was improved by adding TACE to sorafenib if N/L was reduced from ≥2.5 to <2.5 by TACE. Results: The median (interquartile) follow-up for all patients was 8.5 (3.5 to 15.5) with a range from 1 to 71 months. The median (interquartile) survival was 5.0 (2.3-11.3) months for group A and 11.0 (5.0-19.0) months for group B patients (P =.024). In group A, the patients (n = 8) with neutrophil-to-lymphocytes ratio (N/L) < 2.5 had better survival than the patients (n = 9) with N/L ≥ 2.5 (P =.006). In group B, 6 of 13 patients with N/L ≥ 2.5 had N/L reduction to <2.5 after combination therapy of sorafenib and TACE, and their 6-month, 1-year and 2-year survival were improved (P =.013). For immune cell examination, the frequency of CD4+ and CD8+ T-lymphocytes, regulatory T-cell and MDSC were not altered by sorafenib treatment. However, actual number of lymphocytes had a tendency to increase (from 978.5 ± 319.4/mm3 prior to treatment to 1378.0 ± 403.3/mm3, P =.086) for the patients with N/L reduction. Conclusion: Immunosuppressor cells were not altered by sorafeinb. Patients' survival was improved if N/L ≥ 2.5 was reduced to <2.5 by TACE.

原文英語
文章編號e1294
期刊Cancer Reports
卷4
發行號1
DOIs
出版品狀態已出版 - 02 2021

文獻附註

Publisher Copyright:
© 2020 The Authors. Cancer Reports published by Wiley Periodicals LLC.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma」主題。共同形成了獨特的指紋。

引用此